AZN vs. IDXX: A Head-to-Head Stock Comparison

Updated on August 24, 2025

Here’s a clear look at AZN and IDXX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

AZN trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, IDXX is a standard domestic listing.

Symbol	AZN	IDXX
Company Name	AstraZeneca PLC	IDEXX Laboratories, Inc.
Country	United Kingdom	United States
GICS Sector	Health Care	Health Care
GICS Industry	Pharmaceuticals	Health Care Equipment & Supplies
Market Capitalization	249.69 billion USD	51.19 billion USD
Exchange	NasdaqGS	NasdaqGS
Listing Date	May 12, 1993	June 21, 1991
Security Type	ADR	Common Stock

Historical Performance

This chart compares the performance of AZN and IDXX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

AZN vs. IDXX: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	AZN	IDXX
5-Day Price Return	2.95%	-2.16%
13-Week Price Return	12.30%	22.65%
26-Week Price Return	0.63%	39.17%
52-Week Price Return	-9.49%	28.75%
Month-to-Date Return	4.04%	19.75%
Year-to-Date Return	12.55%	54.76%
10-Day Avg. Volume	1.07M	0.52M
3-Month Avg. Volume	1.56M	0.68M
3-Month Volatility	22.19%	60.53%
Beta	0.98	1.58

Profitability

Return on Equity (TTM)

AZN

19.84%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.90%
Q1: 5.63%
Min: -9.96%

AZN’s Return on Equity of 19.84% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.

IDXX

64.42%

Health Care Equipment & Supplies Industry

Max: 34.53%
Q3: 19.38%
Median: 9.52%
Q1: 4.86%
Min: -7.58%

IDXX’s Return on Equity of 64.42% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

AZN vs. IDXX: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Net Profit Margin (TTM)

AZN

14.68%

Pharmaceuticals Industry

Max: 34.51%
Q3: 17.73%
Median: 12.12%
Q1: 5.99%
Min: -7.73%

AZN’s Net Profit Margin of 14.68% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.

IDXX

24.41%

Health Care Equipment & Supplies Industry

Max: 23.34%
Q3: 13.06%
Median: 9.53%
Q1: 5.96%
Min: -3.87%

IDXX’s Net Profit Margin of 24.41% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.

AZN vs. IDXX: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Operating Profit Margin (TTM)

AZN

20.04%

Pharmaceuticals Industry

Max: 41.53%
Q3: 23.00%
Median: 16.24%
Q1: 9.24%
Min: -6.94%

AZN’s Operating Profit Margin of 20.04% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.

IDXX

31.09%

Health Care Equipment & Supplies Industry

Max: 29.44%
Q3: 17.80%
Median: 13.95%
Q1: 8.73%
Min: -3.56%

IDXX’s Operating Profit Margin of 31.09% is exceptionally high, placing it well above the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.

AZN vs. IDXX: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Profitability at a Glance

Symbol	AZN	IDXX
Return on Equity (TTM)	19.84%	64.42%
Return on Assets (TTM)	7.76%	29.89%
Net Profit Margin (TTM)	14.68%	24.41%
Operating Profit Margin (TTM)	20.04%	31.09%
Gross Profit Margin (TTM)	82.07%	61.54%

Financial Strength

Current Ratio (MRQ)

AZN

0.86

Pharmaceuticals Industry

Max: 4.49
Q3: 2.77
Median: 1.74
Q1: 1.26
Min: 0.11

AZN’s Current Ratio of 0.86 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

IDXX

1.11

Health Care Equipment & Supplies Industry

Max: 4.90
Q3: 3.05
Median: 2.14
Q1: 1.49
Min: 0.86

IDXX’s Current Ratio of 1.11 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

AZN vs. IDXX: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Debt-to-Equity Ratio (MRQ)

AZN

0.73

Pharmaceuticals Industry

Max: 2.44
Q3: 1.07
Median: 0.42
Q1: 0.11
Min: 0.00

AZN’s Debt-to-Equity Ratio of 0.73 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

IDXX

0.76

Health Care Equipment & Supplies Industry

Max: 1.49
Q3: 0.71
Median: 0.45
Q1: 0.14
Min: 0.00

IDXX’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.76. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

AZN vs. IDXX: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Interest Coverage Ratio (TTM)

AZN

9.51

Pharmaceuticals Industry

Max: 103.95
Q3: 44.18
Median: 9.83
Q1: 2.82
Min: -42.71

AZN’s Interest Coverage Ratio of 9.51 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

IDXX

49.24

Health Care Equipment & Supplies Industry

Max: 58.29
Q3: 25.56
Median: 9.06
Q1: 3.60
Min: -28.92

IDXX’s Interest Coverage Ratio of 49.24 is in the upper quartile for the Health Care Equipment & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

AZN vs. IDXX: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Financial Strength at a Glance

Symbol	AZN	IDXX
Current Ratio (MRQ)	0.86	1.11
Quick Ratio (MRQ)	0.67	0.75
Debt-to-Equity Ratio (MRQ)	0.73	0.76
Interest Coverage Ratio (TTM)	9.51	49.24

Growth

Revenue Growth

AZN vs. IDXX: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

AZN vs. IDXX: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

AZN

2.00%

Pharmaceuticals Industry

Max: 6.98%
Q3: 3.32%
Median: 2.13%
Q1: 0.14%
Min: 0.00%

AZN’s Dividend Yield of 2.00% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

IDXX

0.00%

Health Care Equipment & Supplies Industry

Max: 4.05%
Q3: 1.76%
Median: 0.71%
Q1: 0.00%
Min: 0.00%

IDXX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

AZN vs. IDXX: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Dividend Payout Ratio (TTM)

AZN

59.51%

Pharmaceuticals Industry

Max: 165.20%
Q3: 90.59%
Median: 49.13%
Q1: 28.91%
Min: 0.00%

AZN’s Dividend Payout Ratio of 59.51% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

IDXX

0.00%

Health Care Equipment & Supplies Industry

Max: 160.00%
Q3: 72.47%
Median: 27.49%
Q1: 0.00%
Min: 0.00%

IDXX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

AZN vs. IDXX: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Dividend at a Glance

Symbol	AZN	IDXX
Dividend Yield (TTM)	2.00%	0.00%
Dividend Payout Ratio (TTM)	59.51%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

AZN

29.72

Pharmaceuticals Industry

Max: 42.51
Q3: 26.88
Median: 19.11
Q1: 15.12
Min: 0.00

A P/E Ratio of 29.72 places AZN in the upper quartile for the Pharmaceuticals industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

IDXX

51.66

Health Care Equipment & Supplies Industry

Max: 73.48
Q3: 51.69
Median: 34.31
Q1: 25.74
Min: 11.47

IDXX’s P/E Ratio of 51.66 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

AZN vs. IDXX: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Price-to-Sales Ratio (TTM)

AZN

4.36

Pharmaceuticals Industry

Max: 7.55
Q3: 4.54
Median: 2.11
Q1: 1.52
Min: 0.00

AZN’s P/S Ratio of 4.36 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

IDXX

12.61

Health Care Equipment & Supplies Industry

Max: 9.53
Q3: 5.26
Median: 3.39
Q1: 2.13
Min: 0.00

With a P/S Ratio of 12.61, IDXX trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

AZN vs. IDXX: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Price-to-Book Ratio (MRQ)

AZN

4.74

Pharmaceuticals Industry

Max: 9.78
Q3: 4.96
Median: 2.23
Q1: 1.46
Min: 0.60

AZN’s P/B Ratio of 4.74 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

IDXX

29.57

Health Care Equipment & Supplies Industry

Max: 10.85
Q3: 5.98
Median: 3.48
Q1: 2.43
Min: 0.69

At 29.57, IDXX’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

AZN vs. IDXX: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Valuation at a Glance

Symbol	AZN	IDXX
Price-to-Earnings Ratio (TTM)	29.72	51.66
Price-to-Sales Ratio (TTM)	4.36	12.61
Price-to-Book Ratio (MRQ)	4.74	29.57
Price-to-Free Cash Flow Ratio (TTM)	30.13	65.76